T
he PKC (protein kinase C) serine-threonine kinases function downstream of multiple membraneassociated signal transduction pathways.
1,2 Approximately 10 different isozymes comprise the PKC family, which are broadly classified by their activation characteristics. The conventional PKC isozymes (α, β-I, β-II, and γ) are Ca 2+ -and lipid-activated, whereas the novel isozymes (ε, θ, η, and δ) and atypical isozymes (ζ and λ) are Ca 2+ independent but activated by distinct lipids.
1,2 PKC-α is the predominant isozyme expressed in the mouse, human, and rabbit heart 3, 4 and is a wellestablished regulator of myocardial function.
Several reports have associated PKC-α activation or an increase in PKC-α expression with hypertrophy, cardiomyopathy, ischemic injury, or neuroendocrine stimulation. 1, 2 Conversely, PKC-α deficiency enhances cardiac contractility and protects against heart failure in multiple model systems, including thoracic aortic constriction, 5 Csrp3 deletion, 5 and infarction. 6, 7 Pharmacological inhibition of PKC-α with the mixed PKC-α/β inhibitor ruboxistaurin enhances contractility and cardioprotection in small and large animal models. [7] [8] [9] The wealth of evidence establishing PKC-α as a regulator of cardiac function and injury suggests PKC-α inhibition as a strategy to treat heart disease. 10 PKC-α is elevated in the failing human myocardium, 11, 12 yet there is no experience assessing the impact of PKC-α inhibition on human myocardial function.
Numerous therapeutic strategies discovered in animal models have failed to translate to effective therapeutics in clinical practice. There are many potential explanations, including species differences and effects of exposures and comorbid conditions on disease progression in patients. Genetic studies have been proposed as an alternative approach to discover targets of higher therapeutic relevance to human disease. 13 A wellknown recent example is discovery of loss-of-function mutations in PCSK9 associated with extremely low levels of low-density lipoprotein cholesterol. 14 This genetic finding inspired development of antibody-based PCSK9 inhibitors now in clinical use to dramatically lower low-density lipoprotein. 15 Discovery of loss-of-function mutations in ANGPTL3 provides a similar example that has inspired new therapeutics. 16, 17 In previous work, we 18 and others 19 have discovered a locus marked by the common variant rs9912468 that potently associates with PKC-α transcript abundance in the human left ventricle (LV). This variant resides within an intronic region of the PRKCA gene encoding PKC-α and, therefore, marks a cis expression quantitative trait locus (eQTL) for PRKCA. Here, we leverage this genetic finding to ask whether an inherited tendency to have low ventricular PKC-α is cardioprotective in human subjects. Unlike findings in animal models, variants that reduce LV PKC-α associate with adverse cardiac remodeling and cardiomyopathy risk. These findings support PKC-α as regulator of the human heart but raise the possibility that PKC-α inhibition may incur cardiac risk depending on timing and duration.
METHODS

Human Myocardium
The data, analytic methods, and study materials have been made available to other researchers for purposes of reproducing the results or replicating the procedure. 20 MAGNet (Myocardial Applied Genomics Network; www.med.upenn. edu/magnet) collects and banks human cardiac tissue for genomic research. All subjects or next of kin provided written informed consent for tissue donation and analyses, and relevant institutional review boards approved all study protocols. LV free-wall tissue was harvested at the time of cardiac surgery from subjects with heart failure undergoing transplantation and from unused donor hearts with apparently normal function. In each case, the heart was perfused with cold cardioplegia before cardiectomy to arrest contraction and prevent ischemic damage, and tissue specimens
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were frozen in liquid nitrogen. DNA was extracted using the Gentra Puregene Tissue Kit (Qiagen, CA), and total RNA was extracted using the miRNeasy Kit (Qiagen). DNA concentration and quality was assessed using gels and PicoGreen. RNA concentration and quality was assessed using the NanoVue Plus spectrophotometer (GE Healthcare) and the Agilent 2100 RNA NanoChip. The final data set comprised 313 samples.
Fine Mapping and Annotation of the PRKCA eQTL DNA samples were genotyped using the Affymetrix Genome-Wide SNP Array 6.0. We excluded samples with cryptic relatedness and limited the samples to genetically inferred European-descent by multidimensional scaling of all genotypes. We eliminated single-nucleotide polymorphisms (SNPs) with call rate <95%, minor allele frequency <15%, or departure from Hardy-Weinberg equilibrium (P<10 −6 ). A minor allele frequency cutoff of 15% rather than the typical 5% used in large-cohort genome-wide association study (GWAS) was used to ensure that adequate numbers of minor allele homozygotes would be available in our sample of 313 subjects. All alleles are encoded on the forward strand. To enable finer genotype coverage, imputation with SNP genotypes in the 1000 Genomes Project was performed and filtered using a quality threshold of 0.5 and a minor allele frequency threshold of 0.15. RNA was hybridized with Affymetrix Genechip ST1.1 arrays using manufacturer instructions. CEL files were normalized with robust multiarray analysis, 21 and expression values were further adjusted for potential batch effects using ComBat. 22 The final data set comprised 313 European ancestry participants and 15 390 robust multiarray analysis expression levels.
Genome-wide associations between transcript abundance and genotypes were tested using an additive genetic model adjusting for age, sex, study site, and patient group (explanted hearts or unused donors) implemented in the R statistical programing language. For each significant locus, associations were retested after conditioning against the strongest expression SNP (eSNP) at that locus to determine a set of minimal eSNPs that mark independent eQTLs. We have previously reported a genome-wide significant cis eQTL for PRKCA marked by the common variant rs9912468. 18 In this report, we use the same data set to focus on associations between all available genotypes in linkage disequilibrium (R 2 ≥0.8) with rs9912468 and their association with PKC-α transcript levels in the LV. Associations between genotypes near rs9912468 and PKC-α transcript abundance in multiple human tissues were assessed using the Genome Tissue Expression database. 23 Predicted regulatory elements in linkage disequilibrium (R 2 ≥0.8) with rs9912468 were mapped using results from human LV ChIP-seq experiments performed by the Roadmap Epigenomics project using ChromHMM (http://compbio. mit.edu/ChromHMM/). ChromHMM is a software package that predicts chromatin regulatory states from the integration of multiple histone modifications assayed by ChIP-seq. 24 ChromHMM data from LV were downloaded as a BED file and were tested for overlap with LV eSNP using the intersect function of the BEDTools suite. 25 Regional association plots were constructed using the locusZoom web interface (http:// locuszoom.org/). In silico prediction of enhancer-binding proteins was attempted using snp2TFBS (http://ccg.vital-it.ch/snp2tfbs/), ePOSSUM (http://mutationtaster.charite.de/ePOSSUM/), and motifBreakR (http://simon-coetzee.github.io/motifBreakR/) applied to the HOCOMOCO transcription factor binding site database. SNP2TFBS reported no results, and motifBreakR showed no significant results after multiple test corrections were applied (Table I in the Data Supplement).
PKC-α Protein Studies
A subset of the eQTL study cohort was selected and comprised 20 patients with dilated cardiomyopathy (DCM) who were homozygous for the major (C) or minor (G) rs9912468 allele and who showed high or low PKC-α gene expression by microarray. For each, ≈100 mg of LV tissue was homogenized in 3 mL of triton lysis buffer (150 mmol/L NaCl, 50 mmol/L Tris pH 8.0, 1% Triton X-100, protease, and phosphatase inhibitors). Thirty micrograms of protein were loaded on 10% acrylamide gels for Western blotting. Immunoblots were performed using a primary antibody directed against PKC-α (SantaCruz H-7; sc-8393, dilution 1:500) and a fluorescent goat antimouse IgG1 secondary antibody (LI-COR, dilution 1:3000) in combination with an Odyssey CLx Infrared Imaging System (LI-COR). GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Fitzgerald; 10R-G109A, dilution 1:20 000) was used as a loading control. Western blots were quantified using Image Studio software (LI-COR). Protein extraction and sample preparation were processed in a blinded manner until Western blot loading.
Generation of Reporter Plasmids
The PRKCA enhancer region was amplified using PCR from human genomic DNA (F: ATAAAGCTGAGTTGTCGGGC; R: TGTGCACAAACGATACTGTCA) and cloned into a Firefly luciferase reporter vector (pGL4.23; Promega) upstream of a cytomegalovirus minimal promoter. A similar plasmid with the enhancer region replaced by a random noncoding genomic segment was constructed for use as a negative control. A reporter vector containing renilla luciferase was used as a control for cell number and transfection efficiency. Sitedirected mutagenesis was used to construct reporters for the 4 enhancer haplotypes using a single clone of the PRKCA enhancer region. This was accomplished using the Q5 Site Directed Mutagenesis kit (New England Biolabs) and back-toback PCR primers (F: GCAGAGGCGGTCCGGAGCGGC; R: CGCCGCGAGTAGGAAACGCGAG) containing the desired substitutions (major and minor alleles at rs9910355 and rs9303504). Sanger sequencing was performed on all plasmids to confirm mutagenesis efficacy.
Cell Culture
HeLa cells were grown under standard conditions (37°C, 5% CO 2 ) in DMEM with l-glutamine (4.5 g/L), sodium pyruvate (4.5 g/L), 10% fetal bovine serum, penicillin (100 U/ mL), and streptomycin (100 μg/mL) and maintained until 100% confluent. HL-1 cells were grown on gelatin-fibronectin-coated plates under standard conditions in Claycomb medium supplemented with 0.1 mmol/L norepinephrine, 2 mmol/L l-glutamine, 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 μg/mL) and maintained until 100% confluent. Neonatal rat ventricular myocytes were isolated using a protocol approved by the Institutional Animal Care and Use Committee. Sprague-Dawley day 0 to 1 pups were euthanized by decapitation; hearts were immediately extracted; the atria and great vessels were removed, and the LV tissue was minced and subjected to a trypsin-based disaggregation procedure. Minced ventricular tissue was rinsed with Hanks balanced salt solution with 1% penicillin/ streptomycin/glutamine and placed in a 50 mL conical tube containing 10 mL of trypsin and placed in a shaking incubator (200 rpm at 37°C) for 15 minutes. The supernatant was discarded after incubation, and trypsin procedure repeated for an additional 7×. After the eighth trypsin treatment, the cells were centrifuged at 660 rpm at 4°C for 5 minutes, and the supernatant was discarded. The remaining cell pellet was resuspended in 20 mL of growth media composed of 4:1 ratio of DMEM and Medium-199, 10% horse serum, 5% fetal bovine serum, 1% HEPES, and 1% solution of penicillin, streptomycin, and glutamine and preplated for 1 to 3 hours in an incubator. Harvested cells were collected after centrifugation at 660 rpm for 5 minutes at room temperature and plated on fibronectin-coated plates. Growth media was replaced 24 hours after harvest.
In Vitro Enhancer Assays
Cells were seeded in 24-well plates with antibiotic-free media and transiently transfected at ≈70% confluency with reporter vectors containing the predicted enhancer and cotransfected with the renilla luciferase reporter. Transfection was performed using Lipofectamine 3000 (Invitrogen) according to manufacturer's instructions and repeated in 3 independent experiments with 4 biological replicates per experiment. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) according to manufacturer's instructions. Seventy-two hours after transfection, cells were washed with PBS and lysed with 100 μL of passive lysis buffer for 15 minutes on a shaker. Twenty microliters of the lysate was transferred into a 96-well plate, and 100 μL of luciferase assay reagent II was dispensed into each well. The plate was placed in a luminometer (Biotek) and measured for 10 seconds. After the initial measurement, 100 μL of Stop & Glo reagent was added into each well to stop the firefly reaction and start the renilla reaction. Measurements were then repeated in 10-second periods in the luminometer. Bioluminescence was collected as a ratio of firefly:renilla and then standardized to the negative control for each condition and reported as luciferase activity relative to the negative control. Two-tailed t tests were performed for all luciferase assays with a P value cutoff of 0.05 for statistical significance with the exception of the PRKCA enhancer assay showing allelic differences in enhancer activity. For that experiment, a linear regression was performed that modeled for the genotype at each SNP and an interaction between the 2 SNPs. This methodology allowed us to test whether the genotype at each SNP produced an effect on luciferase expression and whether the genotypes at the 2 SNPs acted together to produce synergistic effects on luciferase expression.
Zebrafish Studies
Zebrafish experiments were performed using standard protocols approved by the Institutional Animal Care and Use Committee. For enhancer activity screening, the predicted enhancer region was cloned into a tol2-flanked enhanced green fluorescent protein (eGFP) reporter vector upstream of a CMV minimal promoter for injection into zebrafish embryos. Zebrafish embryos were microinjected at the single-cell stage with the vector (25 ng/μL) along with transposase mRNA (10 ng/μL). Fluorescent reporter activity was assayed at 72 hours post-fertilization. Low-magnification micrographs, which detail expression across the entire embryo, were acquired on an Olympus SZX16 fluorescent dissecting microscope. For highresolution images of cardiac-specific expression, embryos were anesthetized in tricaine, and hearts were manually excised. After 30 minutes of fixation in 4% paraformaldehyde, hearts were counterstained in rhodamine-labeled phalloidin and mounted using Vectashield. A z-series of micrographs were acquired on a Zeiss 510 confocal microscope using a 63×1.4 NA oil immersion lens with 4-μm section separation. Final images represent a 2-dimensional projection of the entire acquisition stack.
For analyzing the effects of PRKCA knockdown on cardiac structure, we performed morpholino-mediated knockdown as described. 26 Antisense morpholino oligonucleotides targeting the third exon-intron junction of PRKCA (5′-GCGCATTTGCATACTTACATCTGTA-3′; Genetools, LLC) were injected into the yolk of single-cell zebrafish embryos. At 72 hours post-fertilization, embryos were either collected for analysis of knockdown efficiency or analyzed for cardiac dimensions. For calculations of knockdown efficiency, RNA was collected using the quick-RNA mini kit (Zymo Research) and reverse transcribed using iScript (BioRad, Inc). Amplification of PRKCA was performed using primers spanning from exon 1 to 5. Percent knockdown was measured using ImageJ. Gross morphology was examined using an Olympus SZX16 fluorescent dissecting microscope. Analysis of cardiac dimensions was performed on excised hearts, which were then stained with rhodamine-labeled phalloidin (SigmaAldrich) and imaged on a Zeiss LSM510 confocal microscope at ×20 magnification. 2-Dimensional projections of z-series were generated by averaging all frames, with dimensions measured using ImageJ. Statistical comparisons for longitudinal and transverse dimensions of the ventricle were compared using 2-way ANOVA in Graphpad Prism7.
Association Between rs9912468 and Cardiac Structure, Function, and Failure in Human Populations
We leveraged extant GWAS data to assess the effect of rs9912468 on cardiac structure and function in communitybased cohorts. We began by leveraging GWAS data that has determined the association between common variants and the QRS interval, an electrocardiographic measure of LV mass. 27 Four related and clinically applied QRS quantitative traits were assessed: the Sokolow-Lyon, 28, 29 Cornell, [29] [30] [31] 12-lead-voltage duration products (12-leadsum), 29, 31 and QRS duration. 28 Briefly, GWAS summary data were combined from 24 studies with up to 2 766 983 autosomal SNPs. These studies together comprise 60 255 individuals of European ancestry ascertained in North America and Europe, with a maximum sample size of 54 993 for Sokolow-Lyon, 58 862 for Cornell, 48 632 for 12-leadsum, and 60 255 for QRS duration. For each SNP, evidence of association was combined across studies using an inverse-variance fixed-effect meta-analysis performed by 2 independent groups.
Next, we leveraged GWAS data from the EchoGen consortium 32 to determine the association between rs9912468 echocardiographic measured LV mass, LV end-diastolic dimension, LV wall thickness, and LV fractional shortening. This meta-analysis included up to 7 cohorts with total sample sizes up to 11 314 for our traits of interest. Each cohort ran individual linear regression models, and data from all cohorts were then combined using inverse variance-weighted fixedeffects meta-analysis after applying genomic controls to each cohort.
For all-cause heart failure in the general population, we obtained association summary statistics 33 The analysis included a total of 20 926 participants free of clinical heart failure at baseline, in whom 2526 incident heart failure events occurred during follow-up. Definitions of heart failure varied between the 4 contributing study cohorts. ARIC relied on International Classification of Diseases, Ninth Revision, codes collected from hospital discharge summaries and death certificates. For CHS, FHS, and RS, heart failure events were identified by self-report or administrative data and were validated by physician's review of medical records. CHS and FHS applied their published criteria, and RS applied the European Society of Cardiology criteria. All studies imputed their data to HapMap for genome-wide association analyses using Cox proportional hazards regression and performed study-specific quality control. After applying genomic controls to each cohort, data from the 4 cohorts were meta-analyzed using inverse variance-weighted fixed-effects meta-analysis.
For prevalent DCM in referral cohorts, we tested the association between rs9912468 and odds of DCM in a meta-analysis of a new case-control GWAS (MAGNet association study; 631 cases with DCM and 1596 controls) and a previously published DCM GWAS (Meder et al 34 ; 909 DCM cases and 2120 controls). For the MAGNet association study, we recruited 631 subjects with DCM defined as patients with heart failure and an ejection fraction <40% in the absence of hypertension, primary valvular disease, or coronary artery disease from the University of Pennsylvania Health System and compared them to controls recruited from the same center who had no history of heart disease. All subjects provided written informed consent. Whole-genome SNP genotypes for cases and controls were generated using the Illumina OmniExpressExome Array and were imputed to SNP genotypes in the 1000 Genomes Project using Minimac. 35 We compared genotypes between cases and controls using an additive genetic model adjusting for sex and 2 principal components of race using SNP test. There was minimal genomic inflation (λ=1.0335). To increase power, we meta-analyzed these findings with those from Meder et al using METAL. 36 The effective total sample size was 4342, and there was no evidence of heterogeneity by study (I 2 =18.5%; heterogeneity P=0.27).
RESULTS
Fine Mapping of the PRKCA eQTL Reveals a Cardiac-Specific Enhancer
As previously described, 18 we performed genomewide eQTL mapping in 313 human LVs from patients of European genetic ancestry (Table 1) and identified a genome-wide significant association between variants at rs9912468 and expression of PRKCA. Minor allele carriers (forward strand G) at rs9912468 showed substantially decreased LV PKC-α transcript levels both in the absence and in the presence of heart failure (Figure 1A ; P=1×10 −41 ). No other LV transcripts showed significant association with rs9912468. Western blotting in human LV samples verified that minor allele carriers showed lower PKC-α protein abundance ( Figure 1B  and 1C) . Moreover, individual measures of transcript and protein abundance were strongly correlated (Figure 1D ), indicating that PKC-α transcript abundance is a strong surrogate for PKC-α protein abundance in the human LV. To assess the extent to which rs9912468 affects PRKCA expression in tissues other than the heart, we interrogated eQTL data from the Genome Tissue Expression project ( Figure 1E) . 23 Genotypes at rs9912468 were again strongly associated with LV PKC-α transcript levels. No other tissue showed statistically significant associations after Bonferroni correction for multiple comparisons.
To understand the locus marked by rs9912468 in detail, we constructed a fine map using 1000 Genomes imputation to test associations between LV PRKCA expression and genotypes near rs9912468. This revealed a ≈20-kb block containing multiple variants that strongly associated with PRKCA expression and were in strong linkage disequilibrium (R 2 ≥0.8) with the sentinel rs9912468 variant. We denote this 20-kb region as the PRKCA eQTL (Figure 2 ). Roadmap epigenomic histone marks (H3K4me1 and H3K27ac) from human LV ChIP-seq experiments and predicted enhancer regions from ChromHMM revealed that this region contains a single putative enhancer. Two common SNPs (rs9910355 and rs9303504) associated with PRKCA expression physically reside within this enhancer and are in perfect linkage disequilibrium with rs9912468 ( Figure 2) .
To test enhancer function and specificity in vivo, EGFP constructs containing the cloned enhancer region were microinjected into zebrafish embryos at the single-cell A, Human LV free-wall PKC-α (protein kinase C-α) transcript abundance versus rs9912468 genotype in patients without (n=136) and with (n=177) heart failure. The minor allele at rs9912468 (forward strand G) is associated with lower PKC-α transcript levels (joint effects P=1×10 −41 ). B, Western blot comparing LV PKC-α protein levels in rs9912468 major allele homozygotes (CC, blue) and minor allele homozygotes (GG, red) in a subset of the patients in (A). C, Quantitative analysis using densitometry (n=20) demonstrated reduced PKC-α protein in minor allele homozygotes (P<0.001). D, PKC-α transcript and protein levels assessed in the same subjects showed strong correlation, indicating that PKC-α transcript level is an accurate surrogate for protein level in the human LV. E, Association between rs9912468 genotype and PKC-α transcript levels in multiple human tissues based on Genome Tissue Expression data (*Bonferroni P<0.05). Associations are strongest in LV. RMA indicates robust multiarray analysis.
stage. Survey of EGFP expression post-injection at 72 hpf revealed marked EGFP expression in cardiac tissue ( Figure 3A) . Expression of EGFP was also observed to a lesser degree in skeletal muscle cells. Closer interrogation of cardiac EGFP expression within the isolated zebrafish heart ( Figure 3B ) suggested preferential expression in the ventricle relative to the atrium. To quantify enhancer activity in noncardiac and in cardiac cells, we cloned the predicted enhancer upstream of firefly luciferase and transfected a noncardiac cell line (HeLa), the cardiac-derived HL-1 myoblast cell line, and freshly isolated neonatal rat ventricular myocytes. As shown in Figure 3C , the enhancer region increased luciferase activity ≈5-fold in cardiac-derived (HL-1 and LocusZoom plot of associations between genotypes surrounding rs9912468 and LV PKC-α (protein kinase C-α) transcript levels were assessed in n=313 patients. The rs9912468 variant marks a single linkage disequilibrium block within intron 2 of PRKCA that contains variants strongly associated PKC-α transcript levels. Within this block is a single putative enhancer based on ChromHMM analysis of human epigenomic data, including results from ChIP-seq experiments assessing enhancer marks H3K27ac (blue) and H3K4me1 (green) in human LV tissue. We cloned this region for functional study (putative enhancer). SNP indicates single-nucleotide polymorphism.
neonatal rat ventricular myocytes) but not in HeLa cells. Thus, human eQTL data and in vivo and in vitro functional assays all support that the region of interest is a cardiac-specific enhancer. Potential binding proteins for this enhancer are unknown and could not be reliably predicted by in silico algorithms.
Effect of Enhancer Haplotypes on PRKCA Expression
The variants rs9910355 and rs9303504 described above physically reside within the enhancer and together define 4 haplotypes. To compare their activity, we cloned the enhancer region, performed site-directed mutagenesis to produce all 4 haplotypes, and compared their ability to drive a luciferase reporter in neonatal rat ventricular myocytes ( Figure 3D ). Regardless of haplotype, cells transfected with the enhancer sequence showed increased luciferase activity when compared with control. We found that haplotypes containing the minor allele, G, at rs9303504 showed a 40% decrease in luciferase activity compared with the major allele, C (P=0.004), whereas luciferase activity was unaffected by genotype at rs9910355 (P=0.8). These findings Figure 3 . Cardiac-specific PRKCA enhancer activity and identification of a low-activity enhancer haplotype. A, The cloned human PRKCA enhancer was inserted into an EGFP reporter construct and microinjected into zebrafish embryos. Fluorescent microscopy was used to detail enhancer activity (green). Cardiac-specific activity was evident (arrow) in vivo. B, 2-Dimensional projections of confocal z-series through excised zebrafish hearts suggest greater enhancer activity (green) in the ventricle (V) when compared with the outflow tract (OF) or atrium (A). The red channel displays the distribution of F-actin with nuclei in blue. C, The cloned human PRKCA enhancer was inserted into a luciferase reporter construct and activity was measured relative to a negative control construct after transfection into different cell types. Enhancer activity was evident after transfection into cardiac-derived cells (the HL-1 cell line and primary neonatal rat ventricular myocytes [NRVM]) but not after transfection in noncardiac cells (HeLa cell line). Error bars represent SEs for 3 biological replicates for HeLa and HL-1 and 4 biological replicates for NRVM. D, Site-directed mutagenesis was used to create the 4 enhancer haplotypes observed in humans by altering genotypes at rs9910355 and rs9303504. These were incorporated into luciferase reporter constructs and assessed in vitro. All haplotypes were inactive after transfection into HeLa cells but were active in NRVMs. Enhancer activity was 40% lower for haplotypes containing the minor allele (G) at rs9303504. These low-activity haplotypes are in perfect linkage disequilibrium (R 2 =1.0) with the minor allele (G) at the sentinel variant rs9912468 described in Figure 1 . Error bars represent SEs of 4 biological replicates. Ctrl indicates control. *P<0.05 vs control. †P<0.05 vs haplotype-AC.
parallel the expected directionality based on the eQTL associations in the human LV. That is, the minor allele, G, at the lead SNP rs9912468 marks a PRKCA enhancer haplotype containing a minor allele at rs9303504 that reduces enhancer activity and LV PRKCA expression.
rs9912468 Minor Allele G Associates With Adverse Remodeling, Impaired Contractile Function, and DCM Having established that the minor allele at rs9912468 tags a cardiac-specific enhancer with reduced activity and reduced ventricular PRKCA expression, we assessed the impact of PRKCA through expression modulation in the zebrafish embryo and through examination of rs9912468 genotypes in human subjects using extant GWAS data. After knockdown in zebrafish, no effect on ventricular dimensions was observed ( Figure I in the Data Supplement), although embryonic phenotypes may not be the most appropriate model of adult cardiomyopathy. For human analyses, traits interrogated include measures of LV mass, dilatation, wall thickness, contractile function, all-cause heart failure in the community, and DCM in referral cohorts ( Table 2 ). The PKC-α-lowering allele (G) at rs9912468 is associated with increased LV mass measured by electrocardiogram 27 using the Cornell voltage criteria (P=0.0026), 12-lead sum area (P=4.99×10 −11 ), Sokolow-Lyon area (P=3×10 −12 ), and QRS duration (P=1.65×10 −11 ). In the EchoGEN Consortium, 32 the PKC-α-lowering allele associated with increased LV internal diastolic dimension (P=0.0003), thinning of the LV wall (P=0.0039), and a potential decrease in fractional shortening (P=0.039). An association with LV mass by echocardiogram was not observed, nor was there an association with incident all-cause heart failure in the community in the CHARGE consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology). 33 In a meta-analysis of a new and a previously published 34 DCM casecontrol GWAS, the PKC-α-lowering allele associated with DCM (odds ratio, 1.19; P=0.0012). The directionality across all associations is consistent and suggests that individuals inheriting the PKC-α-lowering allele have higher LV mass, more LV dilation, LV wall thinning, and higher risk of clinically diagnosed DCM.
DISCUSSION
This report combines genetic, transcriptomic, and epigenetic data to uncover a cardiac-specific enhancer that regulates PRKCA expression in the human LV. Common variants within this enhancer potently affect expression of PRKCA in the human heart, but not in other tissues, and functional studies in vitro and vivo verify that enhancer activity is specific to the heart. Paradoxically, minor allele carriers at rs9912468, which marks the enhancer haplotype that reduces PKC-α in the LV, show increases in adverse cardiac remodeling and cardiomyopathy risk. In sum, these data suggest a mechanism whereby minor allele carriers inherit genetically blunted LV PRKCA expression that causes mild adverse effects on the human heart.
Li et al 37 recently reported an allelic imbalance study in 51 LV tissue specimens that associates the minor allele at rs9909004 with lower PKC-α transcript abun- dance. Further, they speculate that this allele could have favorable cardiac effects because it associates with a shortening of the electrocardiographic QT interval in a GWAS meta-analysis of cardiac repolarization. 18 The rs9909004 variant is in perfect linkage disequilibrium with rs9912468 (R 2 =1.0) and thus marks the same locus studied herein with the same reported effect on PKC-α reduction. However, Sotoodehnia et al 38 demonstrate that although the minor allele at this locus associates with QT shortening and may reduce the risk of torsade de pointes, the same allele also associates with QRS prolongation and may promote heart failure through LV dyssynchrony. These discordant effects on QRS and QT intervals are evident for several loci that affect electrocardiographic traits. 38 To shed more light on the clinical impact of the PKC-α-lowering allele, we examined associations with additional cardiac traits (Table 2) . Overall, these show a pattern that is not favorable, with increased LV mass by electrocardiogram and echo, more ventricular dilatation, and higher risk of clinically diagnosed cardiomyopathy.
These findings seem to contradict previously published animal studies. Whereas studies in rodents and pigs found cardioprotective effects of PKC-α inhibition, [5] [6] [7] [8] our genetic data suggest adverse effects. There are several potential explanations for this paradox. Species differences are an obvious consideration. Alternatively, the discrepancy between our human genetic and previous animal studies may reflect differences in dosage and time course of change in PKC-α activity. Whereas pharmacological inhibition in animal studies occurs in the acute setting with near-complete abolishment of PKC-α activity, the variant in our study is associated with a lifelong and partial decrease in PRKCA expression. It may be reasonable to expect differential cardiac effects of reduced PKC-α during the preclinical phase of heart failure development compared with PKC-α inhibition in established heart failure. Even among patients with established heart failure, there is tremendous heterogeneity in pathogenic factors, severity of disease, treatment approaches, and disease setting (eg, chronic heart failure versus acutely decompensated heart failure). Given previously observed inotropic effects of PKC-α inhibition in animal models, 6 PKC-α inhibition may have use in acute settings but toxicity in the setting of heart failure prevention. Detailed study of the effects of the PRKCA eQTL on human LV PKC-α activity and the phosphorylation state of PKC-α targets may provide additional insights.
The convergence of work in animal models and in human genetics identifying PRKCA as a modifier of myocardial disease raises its profile as a pharmacological target. However, the path forward for drug development is not obvious. Currently, there is no experience assessing the impact of PKC-α inhibition on human myocardial function. The only cardiovascular analysis of PKC-α inhibition in humans comes from studies with ruboxistaurin, a mixed PKC-α and PKC-β inhibitor. In 2 separate early-phase trials, ruboxistaurin administration in diabetics induced improvements in flow-mediated 39 and methacholine-mediated 40 peripheral artery dilatation. Microvascular effects have been assessed in ≈1400 patients with diabetic retinopathy across many clinical trials. Interestingly, aggregate analysis of these trials suggests a reduction in all-cause mortality with ruboxistaurin. 41 Assessing therapeutic potential in human heart failure will require carefully designed pharmacological studies to determine which subgroups might or might not benefit. These studies should consider the pharmacogenomic implications of the PRKCA eQTL in their design.
A final observation of importance is that there are clearly endophenotypes of heart failure that have distinct genetic architectures. The PRKCA eQTL had a consistent influence on heart failure characterized by LV dilatation, reduction in contractile function, and increased risk of DCM. But there was no discernible effect on all-cause heart failure in the community, a heterogeneous phenotype that also includes heart failure with preserved ejection fractions and ischemic heart disease. Precise definition of heart failure subtypes should increase our ability to elucidate the genetic architecture of myocardial disease, which likely differs across subtypes.
In conclusion, we uncovered common enhancer variants that reduce PRKCA expression in the human heart and in so doing affect cardiac structure, function, and disease. These findings support PKC-α as regulator of the human heart but raise the possibility that PKC-α inhibition may incur cardiac risk depending on timing and duration. Pharmacological studies in human subjects are required to discern the potential benefits and harms of PKC-α inhibitors as an approach to treat heart disease.
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